{'fraction_non_alphanumeric': 0.04050833995234313, 'fraction_numerical': 0.026211278792692614, 'mean_word_length': 4.384615384615385, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Overexpression of HLA-DR is associated with prognosis of glioma patients.

AIMS
Since the poor prognosis of glioma, our study was aimed to find out the role of HLA-DR in the prognosis of glioma patients that may contribute to the timely post-operative treatment on the glioma patients.


METHODS
60 glioma patients were enrolled in the prospective cohort study. Western blotting was used to detect the content of HLA-DR. Kaplan-Meier curve was adopted to evaluate the effects of HLA-DR on the survival time of glioma patients. Cox regression analysis was used to evaluate the roles of clinical features and HLA-DR in the pathogenesis of glioma.


RESULTS
The expression level of HLA-DR was higher in tumor tissue, compared with normal tissues (P<0.05). Moreover, expression levels of HLA-DR were correlated with the factors of pathological degree, Enneking staging and KPS score. The survival rate of patients with high content of HLA-DR was lower than those of patients with low content of HLA-DR. Cox regression analysis indicated that Enneking staging and HLA-DR were all associated with the prognosis of glioma (HR=14.43, 95% CI=1.05-199.16; HR=21.39, 95% CI=2.07-220.76).


CONCLUSION
HLA-DR may serve as a biomarker for the prognosis of glioma patients.